Systematic Biopsies as a Complement to Magnetic Resonance Imaging-targeted Biopsies: "To Be or Not To Be"?

Johan Stranne; Nicolas Mottet; Olivier Rouvière; EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel

doi:10.1016/j.eururo.2023.01.012

Systematic Biopsies as a Complement to Magnetic Resonance Imaging-targeted Biopsies: "To Be or Not To Be"?

Eur Urol. 2023 May;83(5):381-384. doi: 10.1016/j.eururo.2023.01.012. Epub 2023 Feb 1.

Authors

Johan Stranne¹, Nicolas Mottet², Olivier Rouvière³; EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel

Affiliations

¹ Department of Urology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: johan.stranne@vgregion.se.
² Department of Urology, University Hospital, St. Etienne, France.
³ Department of Radiology, Edouard Herriot Hospital, Lyon, France.

PMID: 36737297
DOI: 10.1016/j.eururo.2023.01.012

Abstract

In light of recent prostate cancer screening programme proposed by the European Association of Urology, there is an urgent need to optimise detection of clinically significant cancer while minimising overdiagnosis. This may be achieved by omitting systematic biopsies while ensuring quality control for diagnostic magnetic resonance imaging and targeted biopsies.

Publication types

Editorial

MeSH terms

Early Detection of Cancer
Humans
Image-Guided Biopsy / methods
Magnetic Resonance Imaging / methods
Male
Prostate / pathology
Prostate-Specific Antigen
Prostatic Neoplasms* / pathology

Substances

Prostate-Specific Antigen